Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Gets CE Mark for PCR-Based Chlamydia Test

NEW YORK (GenomeWeb News) – Abbott Laboratories said yesterday that it has received the CE Mark for a PCR-based test that can detect a new variant strain of Chlamydia trachomatis that has been found in one in five chlamydia cases in Sweden.
 
The assay, which may now be sold for clinical diagnostic use throughout the European Union, is run on Abbott’s automated m2000 real-time PCR system. Abbott said that the assay would be offered in Europe as part of its alliance with Celera.
 
Wide incidence of the mutant strain has been limited to Sweden, according to Abbott, but cases also have been reported in Ireland, Norway, Denmark, and France.
 
Abbott also sells PCR-based assays in Europe for HIV-1, hepatitis C virus, and hepatitis C viral load.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.